1st Edition

The Future of Pharmaceuticals A Nonlinear Analysis

By Sarfaraz K. Niazi Copyright 2022
620 Pages 118 B/W Illustrations
by CRC Press

620 Pages 118 B/W Illustrations
by CRC Press

620 Pages 118 B/W Illustrations
by CRC Press

Before now, biological systems could only be expressed in terms of linear relationships, however, as knowledge grows and new techniques of analysis on biological systems is made available, we are realizing the non-linearity of these systems. The concepts and techniques of nonlinear analysis allow for more realistic and accurate models in science. The Future of Pharmaceuticals: A Nonlinear... Read more

Preface.....................................................................................................................................................xix

Acknowledgments.................................................................................................................................xxvii

Author....................................................................................................................................................xxix

Glossary of Important Terminology......................................................................................................xxxi

1 Understanding Nonlinearity............................................................................................................ 1

2 The Evolution of Pharmaceuticals................................................................................................. 23

3 Artificial Intelligence...................................................................................................................... 69

4 Drug Discovery Trends................................................................................................................... 91

5 Drug Development Assays.............................................................................................................143

6 Nanomedicine................................................................................................................................ 195

7 Antimicrobials................................................................................................................................231

8 Therapeutic Proteins......................................................................................................................251

9 Manufacturing Trends................................................................................................................. 307

10 Therapeutic Protein Delivery Systems........................................................................................ 345

11 Gene and Cell Therapy..................................................................................................................381

12 Nucleic Acid Vaccines....................................................................................................................421

13 Botanical Products........................................................................................................................ 439

14 Regulatory Optimization.............................................................................................................. 469

15 Intellectual Property......................................................................................................................531

Index........................................................................................................................................................557

Biography

Sarfaraz K. Niazi, Ph.D., is an Adjunct Professor at the University of Illinois and University of Houston; he has authored 60+ major books, 100+ research papers, and 100+ patents, mainly in the field of bioprocessing, drug discovery, mRNA vaccines, drug formulations, thermodynamic systems, alcohol aging, nutraceuticals and treatment of autoimmune diseases. He has established multiple biotechnology projects, from concept to market. He also serves as an advisor to major pharmaceutical and biopharmaceutical companies, regulatory agencies, the FDA, the US Congress, and several heads of state. He is also a patent law practitioner.